gel

Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois

NEW YORK, June 22, 2007 /PRNewswire-FirstCall/ -- KeryxBiopharmaceuticals, Inc. today announced that abstracts related toSulonex(TM) (sulodexide oral gelcap) have been selected forpublication or presentation during the poster sessions scheduled totake place at the upcoming American Diabetes Association (ADA) 67thAnnual Scientific Sessions and exposition at the McCormick PlaceLakeside Cen...

Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)

MALVERN, Pa., May 22, 2007 /PRNewswire-FirstCall/ -- AuxiliumPharmaceuticals, Inc. today announced that new data showimprovements in symptoms of decreased libido, energy levels anderectile function in 76 percent of hypogonadal men after switchingbrands of testosterone replacement gel therapy. Total testosteronelevels increased significantly in patients who switched toAuxilium's Testim(R)...

Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth

LIVINGSTON, N.J.--(BUSINESS WIRE)--Apr 26, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) today announced that preliminaryresults from the ongoing data analysis of the recently-completedrandomized, placebo-controlled, double-blind Phase III clinicaltrial of PROCHIEVE(R) 8% (progesterone gel) for the prevention ofpreterm birth in women with a previous preterm birth earlier than35 weeks ges...

terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles

Second generationpyridopyrazine-urea derivative compound series show highlyselective PI3K-inhibition which could be valuable for cancertreatment QUBEC CITY, Canada, April16, 2007 terna Zentaris Inc. (TSX: AEZ; Nasdaq:AEZS), a global, pure play biopharmaceutical company...

AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles

JMR-132 could provide a new therapeutic approach for the treatmentof early and metastatic breast cancer QUEBEC CITY, April 17, 2007 /PRNewswire-FirstCall/ - AEternaZentaris Inc. , a global, pure play biopharmaceutical companyfocused on endocrine therapy and oncology, today presented anabstract outlining in vivo data for its growth hormone-releasinghormone (GHRH) antagonist JMR-132 in brea...

Onconova Therapeutics Announces Presentation of Clinical and Non-Clinical Results for Its Lead Compound ON 01910.Na at American Association of Cancer Research Conference in Los Angeles

LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Apr 16, 2007 - OnconovaTherapeutics, Inc. today announced the presentation of severalscientific studies relating to its lead anticancer drug ON 01910.Naat the Annual Meeting of the American Association for CancerResearch (AACR) being held April 14-18, 2007 in Los Angeles,California. During this meeting, on Sunday, April 15th, Dr. E.Premkumar Reddy, the...

Rigel to Present New Research Programs at AACR Meeting

Focus on Rigel's Extensive Oncology Portfolio SOUTH SAN FRANCISCO, Calif., April 16, 2007/PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. todayannounced the presentation of four research projects aimed atidentifying small molecule inhibitors of select kinases aspotential therapeutics for certain types of cancers and otherdisorders. Rigel scientists will give the presentations during...

AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles

Second generation pyridopyrazine-urea derivative compound seriesshow highly selective PI3K-inhibition which could be valuable forcancer treatment QUEBEC, April 16, 2007 /PRNewswire-FirstCall/ - AEterna ZentarisInc. , a global, pure play biopharmaceutical company focused onendocrine therapy and oncology, today presented an abstractoutlining first in vitro data on its pyridopyrazine derivat...

Cequent Pharmaceuticals Founder to Present tkRNAi Technology at the American Association of Cancer Research Annual Meeting in Los Angeles

CAMBRIDGE, Mass., April 13, 2007 /PRNewswire/ -- CequentPharmaceuticals, a pioneer in the development of novel products todeliver RNAi-based treatments to prevent and treat human disease,announced that its founder, Chiang Li, MD, will present ascientific poster on Cequent's proprietary TransKingdom RNAinterference (tkRNAi(TM)) technology at the 2007 annual meeting ofthe American Associat...

AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles

QUEBEC CITY, April 13, 2007 /PRNewswire-FirstCall/ - AEternaZentaris Inc. , a global, pure play biopharmaceutical companyfocused on endocrine therapy and oncology, today announced that itwill present two abstracts outlining first in vitro data on itsPI3K inhibitors as well as in vivo data on its GHRH antagonist,JMR-132, which both may potentially provide new therapeuticapproaches for the...

Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma

SOUTH SAN FRANCISCO, Calif., April 11, 2007/PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. todayprovided a clinical update on R788, which is currently in ongoingPhase 2 clinical trials in immune thrombocytopenic purpura (ITP),rheumatoid arthritis (RA) and lymphoma patients. R788 is a novel,oral syk kinase inhibitor that blocks the activation of mast cells,macrophages and B-cells th...

Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity

Rigel Program to be Presented at Keystone Scientific Meeting SOUTH SAN FRANCISCO, Calif., March 27, 2007/PRNewswire-FirstCall/ -- Rigel today announced that YonchuJenkins, Ph.D., Associate Director of Virology, will be presentingon the company's efforts to develop a small molecule therapeutic totreat patients with the Human Immunodeficiency Virus (HIV)infection at the Keystone Symposium i...